Cellectis to Present Data on its Allogeneic CAR T-Cell Programs at the 19th American Society of Gene & Cell Therapy Annual Meeting
Published on May 02, 2016
May the 2nd, 2016 – New York (USA) – Cellectis (Alternext: ALCLS – Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced that data on its engineered allogeneic CAR T-cell programs will be featured in three poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 19th Annual Meeting.
The meeting will be held from May 4 to May 7, 2016 in Washington, DC, USA.
Allogeneic CAR T-Cells Targeting CD123 Effectively Eliminate Myeloid Leukemia Cells
Presentation by Julianne Smith, Ph.D., Vice President CART Development at Cellectis
Poster Session: Cancer-Immunotherapy, Cancer Vaccines II
Session Time: Thursday, May 5, 2016, 5:45 PM
Room: Exhibit Hall C & B South
Final abstract number: 397
An Engineered CAR T-Cell Platform for Allogeneic Combination Immunotherapy
Presentation by Philippe Duchateau, Ph.D., Chief Scientific Officer of Cellectis
Poster Session: Cancer-Targeted Gene and Cell Therapy II
Session Time: Friday, May 6, 2016, 6:00 PM - 8:00 PM
Room: Exhibit Hall C & B South
Final abstract number: 676
Integration of Dual Signal Input Strategies in Novel Chimeric Antigen Receptors to Control the CAR T-Cell Functions
Presentation by Alexandre Juillerat, Ph.D., Senior Scientist at Cellectis
Poster Session: Cancer-Immunotherapy, Cancer Vaccines III
Session Time: Friday May 6, 2016 6:00 PM - 8:00 PM
Room: Exhibit Hall C & B South
Final abstract number: 651
Posters will be posted on Cellectis’ website on May 7, 2016.